ACC, Veradigm Partner to Accelerate Treatment for Patients With Diabetes, CV Disease
The ACC and Veradigm have announced a strategic partnership designed to improve care and power the next generation of real-world research on behalf of cardiovascular disease and diabetes patients around the world. The partnership will combine the power of Veradigm with ACC's NCDR PINNACLE Registry and Diabetes Collaborative Registry to create the largest ambulatory chronic disease network in the United States with more than 250,000 clinicians and 100 million patients.
"ACC and Veradigm are transforming how cardiovascular and diabetes care are delivered by providing clinicians access to the right clinical information at the right time to improve the outcomes of their patients," said Richard J. Kovacs, MD, FACC, ACC president. "As information technology transforms how we practice medicine, it is essential that we partner with the most accomplished innovators to ensure our field has full access to the fruit of technology's progress. Our partnership with Veradigm will ensure we continue to meet our commitments to registry participants while preparing to deliver a whole new generation of clinical tools and research opportunities."
In addition to integrating Veradigm's technology and analytic capabilities with the ACC's PINNACLE Registry and Diabetes Collaborative Registry, the partnership will leverage Veradigm's large specialist and primary care provider network on Allscripts and Practice Fusion electronic medical records to bring ACC's clinical guidelines, decision pathways and wealth of provider and patient engagement tools to the point of care.
"Veradigm's focus on leveraging holistically integrated, rapidly available, point-of-care data combined with innovative analytics, reporting and seamless provider workflow interventions fits squarely with ACC's vision of a world where innovation and knowledge optimize cardiovascular care and outcomes," said Stephanie Reisinger, vice president and general manager at Veradigm. "We believe our aligned visions and missions, combined with our collective world-class technology platforms and scientific leadership, make this the most powerful partnership in chronic disease management."
The partnership will expand and enhance the value for patients, providers, health plans, researchers and other stakeholders across the health care ecosystem, while maintaining all the benefits of current participation in the PINNACLE Registry and Diabetes Collaborative Registry. Specifically, patients will have greater opportunities to participate in research studies and have increased access to evidence-based medicine and tools, while providers can expect clinical workflow solutions to be deployed more seamlessly at the point-of-care.
By leveraging registry data, health plans benefit from targeted interventions for disease management and population health initiatives, while life sciences researchers have access to the largest combined cardiovascular database, with over 100 million patients, for a variety of scientific studies. To date, PINNACLE Registry and Diabetes Collaborative Registry research has been used to highlight real-world impacts of new clinical guidelines and identify where gaps in evidence-based care exist.
"The ability to facilitate meaningful change and move the needle in solving the heart disease and cardiometabolic crises facing our world is unprecedented," said Tom Langan, Veradigm CEO. "We look forward to working with the ACC to re-shape the future and improve the lives of patients everywhere."
Keywords: National Cardiovascular Data Registries, PINNACLE Registry, Diabetes Collaborative Registry, Patient Participation, Workflow, Leadership, Population, Diabetes Mellitus, Health Planning, Registries, Research, Electronic Health Records, Cardiovascular Diseases, Heart Diseases, Biological Science Disciplines, Chronic Disease, Ecosystem, Primary Health Care
< Back to Listings